Chronic cerebrovascular diseases, metabolic syndrome, and the hemorrheological and hemostatic systems

  • Authors: Tanashyan M.M.1, Ionova V.G.1, Orlov S.V.1, Omel'chenko N.G.1, Shabalina A.A.1, Kostyreva M.V.1, Tanashyan MM1, Ionova VG1, Orlov SV1, Omelchenko NG1, Shabalina AA1, Kostyreva MV1
  • Affiliations:
  • Issue: Vol 82, No 10 (2010)
  • Pages: 19-24
  • Section: Editorial
  • URL:
  • Cite item


Aim: to study an association between metabolic syndrome and endothelial dysfunction as a regulator of hemorrheological and hemostatic processes in patients with chronic forms of cerebral circulatory insufficiency.
Subjects and methods. Forty-six patients with chronic cerebrovascular diseases (CCVD) were examined; of them 23 patients were diagnosed as having metabolic syndrome (MS). Clinical manifestations and major hemorrheological and hemostatic parameters, such as platelet and erythrocyte aggregation, fibrinogen, hematocrit, von Willebrand factor, antithrombin III, intercellular adhesion molecules (IAM), etc., were estimated. Endothelial dysfunction was studied from the data of cuff test (CT).
Results. MS promotes a higher degree of clinical symptomatology in patients with CCVD and more significant impairments in the hemorrheological and hemostatic systems. CT has shown that all the patients have an inadequate endothelial reaction - the antiaggregatory, fibrinolytic, and anticoagulant activities of the endothelium are lowered. There was endothelium-dependent hyperproduction of IAM.
Conclusion. The found changes suggest that MS has a considerable impact on the formation of a significant procoagulant state of the hemorrheological and hemostatic systems in patients with CCVD.

About the authors

Marine Movsesovna Tanashyan

Viktoriya Grigor'evna Ionova

Sergey Valer'evich Orlov

Nadezhda Grigor'evna Omel'chenko


Alla Anatol'evna Shabalina

Marina Vladimirovna Kostyreva

M M Tanashyan

V G Ionova

S V Orlov

N G Omelchenko

A A Shabalina

M V Kostyreva


  1. Суслина З. А., Пирадов М. А. (ред.) Инсульт: диагностика, лечение, профилактика. М.: МЕДпресс-информ; 2008.
  2. Reaven G. M. Banting lecture: role of insulin resistans in human disease. Diabetes 1988; 37: 1595-1607.
  3. Kaplan N. M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 1989; 149: 1514-1520.
  4. Henefeld M., Leonardt W. Das metabolische Syndrome. Dtsch. Gesundh. - Wes. 1980; 36: 545-551.
  5. Haffner S. M., Valdez R. A., Hazuda H. P. et al. Prospective analyses of the insulin resistance syndrome (Syndrome X). Diabetes 1992; 41: 715-722.
  6. Ройтберг Г. Е. (ред.). Метаболический синдром. М.: Мед-прессинформ; 2007.
  7. Чазова И. Е., Мычка В. Б. Метаболический синдром и артериальная гипертония. Consilium Medicum 2002; 11: 587- 590.
  8. Искандарова Л. Р., Муталова Э. Г., Смакова Э. Р. и др. Молекулы адгезии и клеточно-цитокиновый комплекс в ремоделировании сосудов при артериальной гипертонии с метаболическими факторами риска. Рос. кардиол. журн. 2008; 5: 14-20.
  9. Глотова Н. А. Гематовазальные взаимодействия у больных с асимптомным поражением внутренних сонных артерий: Дис. ... канд. мед. наук. М.; 2009.
  10. Суслина З. А., Танашян М. М., Ионова В. Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. М.: Мед. книга; 2005.
  11. Танашян М. М. Ишемические инсульты и основные характеристики гемореологии, гемостаза и фибринолиза: Дис. ... д-ра мед. наук. М.; 1997.
  12. Adams M. R., Robinson J., McCredie R. et al. Smooth muscle dysfunction occurs independently of impaired endothelium-depedent dilation in adults at risk of atherosclerosis. J. Am. Coll. Cardiol. 1998; 32 (1): 123-127.
  13. Kim S. H., Reaven G. M. The metabolic syndrome: one step forward, two steps back. Diabet. Vase. Dis. Res. 2004; 1 (2): 68-75.
  14. Шестакова М. В. Дисфункция эндотелия - причина или следствие метаболического синдрома? Рус. мед. журн. 2001; 9 (2): 88-92.
  15. Pinkey J. H., Stehouwer C. D., Coppack S. W., Yudkin J. S. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46 (Suppl. 2): 9-13.
  16. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 2001; 22 (1): 36-52.
  17. Arcaro G., Gretti A., Balzano S. et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105: 576-582.
  18. Linderkamp O., Ruef P., Zilow E. P. et al. Impaired deformability of erythrocytes and neutrophils in children with newly diagnosed insulindependent diabetes mellitus. Diabetologia 1999; 42 (7): 865-869.
  19. Brun J. F., Aloulou I., Varlet-Marie E. Hemorheological aspects of the metabolic syndrome: markers of insulin resistance, obesity or hyperinsulinemia? Clin. Hemorheol. Microcirc. 2004; 30 (3-4): 203-209.
  20. Орлов С. В. Гемореология и гемостаз при ишемических инсультах у больных с метаболическим синдромом: Дис. ... канд. мед. наук. М.; 2006.
  21. Иванова О. В., Соболева Г. Н., Карпов Ю. А. Эндотелиальная дисфункция - важный этап развития атеросклеротического поражения сосудов (обзор литературы - 1). Тер. арх. 1997; 6: 75-78.



Abstract - 58



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies